ALC - Alcon - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

44.49B

Cash

1.101B

Avg Qtr Burn

N/A

Short % of Float

0.68%

Insider Ownership

0.14%

Institutional Own.

70.70%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rocklatan (Roclanda - EU) (netarsudil (ROCK - rho kinase inhib) & latanoprost (ophthalmic solution) Details Intra-ocular pressure, Opthalmolgy, Eye disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rhopressa (Rhokiinsa - EU) (netarsudil)(ROCK - rho kinase inhibitor) Details Opthalmolgy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AR-1105 Details Eye disease , Diabetic macular edema, Diabetes	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AR-15512 (TRPM8 agonist eye drop) Details Eye disease , Dry eye syndrome, Opthalmolgy, Metastatic merkel cell carcinoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.